MCID: PNC027
MIFTS: 34

Pancreatic Gastrinoma malady

Categories: Endocrine diseases, Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Pancreatic Gastrinoma

Aliases & Descriptions for Pancreatic Gastrinoma:

Name: Pancreatic Gastrinoma 12 14 69
Pancreatic G-Cell Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5580
NCIt 47 C9069 C95596
UMLS 69 C1368066

Summaries for Pancreatic Gastrinoma

MalaCards based summary : Pancreatic Gastrinoma, also known as pancreatic g-cell tumor, is related to peroneal nerve paralysis and post-vaccinal encephalitis. An important gene associated with Pancreatic Gastrinoma is SCT (Secretin), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Lansoprazole and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include liver and lymph node.

Related Diseases for Pancreatic Gastrinoma

Diseases related to Pancreatic Gastrinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 115)
id Related Disease Score Top Affiliating Genes
1 peroneal nerve paralysis 10.3 CHGA SYP
2 post-vaccinal encephalitis 10.3 GAST SCT
3 brain stem ependymoma 10.3 CHGA SYP
4 non specific chronic endometritis 10.3 CHGA SYP
5 extrahepatic biliary papillomatosis 10.3 CHGA SYP
6 prolactin producing pituitary tumor 10.3 CHGA SYP
7 epithelioid malignant peripheral nerve sheath tumor 10.3 CHGA SYP
8 uterine ligament cancer 10.3 MEN1 SST
9 cartilage cancer 10.3 CHGA SYP
10 postgastrectomy syndrome 10.3 SST SYP
11 burning mouth syndrome type 3 10.3 POMC SST
12 renal hypoplasia, bilateral 10.3 POMC SST
13 villous adenocarcinoma 10.3 CHGA SYP
14 jejunal neuroendocrine tumor 10.3 CHGA SYP
15 malignant granular cell myoblastoma 10.3 CHGA PTHLH
16 water-clear cell adenoma 10.3 POMC SST
17 renal pelvis adenocarcinoma 10.3 CHGA SYP
18 spasmodic dysphonia 10.3 CHGA SYP
19 adult ependymoblastoma 10.2 CHGA MEN1
20 vaginal adenoma 10.2 POMC SST
21 autoimmune pancreatitis 10.2 CHGA GAST
22 gmppa-cdg 10.2 CHGA SCT SST
23 neuritis 10.2 SST SYP
24 barre-lieou syndrome 10.2 CHGA SYP
25 african histoplasmosis 10.2 POMC SST
26 microinvasive cervical squamous cell carcinoma 10.2 CHGA SYP
27 dysgerminoma of ovary 10.2 CHGA MEN1 SYP
28 oculocutaneous albinism 10.2 CHGA SST
29 adult botryoid rhabdomyosarcoma 10.2 CHGA SST SYP
30 cowper gland carcinoma 10.2 CHGA MEN1 PTHLH
31 bone dysplasia azouz type 10.2 CHGA SST SYP
32 myoepithelial carcinoma 10.2 CHGA SST SYP
33 nutritional optic neuropathy 10.2 GAST SST
34 strabismus 10.2 MEN1 PTHLH SYP
35 extragonadal nonseminomatous germ cell tumor 10.2 POMC SST
36 pulmonary neuroendocrine tumor 10.2 MEN1 POMC SST
37 tricuspid valve stenosis 10.2 GAST SCT SST
38 meige syndrome 10.2 CHGA SST SYP
39 rheumatic encephalitis 10.2 MEN1 POMC SST
40 paranasal sinus cancer, adult 10.2 GAST MEN1 SST
41 pancreatitis 10.2
42 gastrinoma 10.2
43 immune system organ benign neoplasm 10.2 MEN1 POMC SST
44 breast secretory carcinoma 10.2 CHGA POMC SST
45 urethra clear cell adenocarcinoma 10.2 MEN1 POMC SST
46 loeffler endocarditis 10.2 MEN1 POMC SYP
47 non-syndromic x-linked intellectual disability 10.2 CHGA POMC SST
48 adamantinous craniopharyngioma 10.2 MEN1 POMC SST
49 secondary syphilis 10.2 CHGA GAST SST
50 brain edema 10.2 CHGA GAST SST

Graphical network of the top 20 diseases related to Pancreatic Gastrinoma:



Diseases related to Pancreatic Gastrinoma

Symptoms & Phenotypes for Pancreatic Gastrinoma

Drugs & Therapeutics for Pancreatic Gastrinoma

Drugs for Pancreatic Gastrinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
2 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
3 pancreatic polypeptide Phase 4,Phase 2,Phase 3,Phase 1
4 Antacids Phase 4,Phase 3,Phase 2
5 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2
6
Dexlansoprazole Phase 4 138530-94-6, 103577-45-3 9578005
7 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
8
Proton pump inhibitors Phase 4,Phase 3,Phase 2
9
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
10
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
11
Levoleucovorin Approved Phase 2, Phase 3,Phase 1 68538-85-2
12
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
13
Esomeprazole Approved, Investigational Phase 3 161796-78-7, 119141-88-7 4594 9579578
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
16
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 54575, 6560146 143
17 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
18 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
19 Antimetabolites Phase 2, Phase 3,Phase 1
20 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
21 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
22 Adjuvants, Anesthesia Phase 3
23 Analgesics Phase 3
24 Analgesics, Opioid Phase 3
25 Anesthetics Phase 3
26 Anesthetics, General Phase 3
27 Anesthetics, Intravenous Phase 3
28 Central Nervous System Depressants Phase 3
29 Narcotics Phase 3
30 Peripheral Nervous System Agents Phase 3
31 Folate Nutraceutical Phase 2, Phase 3
32 Vitamin B9 Nutraceutical Phase 2, Phase 3
33 Cola Nutraceutical Phase 3,Phase 1
34
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
35
Pancrelipase Approved Phase 2,Phase 1 53608-75-6
36
Streptozocin Approved Phase 2 18883-66-4 29327
37
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
38
Omeprazole Approved, Investigational, Vet_approved Phase 2 73590-58-6 4594
39
Pantoprazole Approved Phase 2 102625-70-7 4679
40
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
41
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
42
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
43
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
44
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
45
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
46
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
47
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
48
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
49
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
50
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353

Interventional clinical trials:

(show all 46)
id Name Status NCT ID Phase
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4
3 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3
4 Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome Completed NCT00079833 Phase 3
5 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3
6 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
7 Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas Completed NCT00001165 Phase 2
8 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2
9 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Completed NCT00001191 Phase 2
10 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2
11 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2
12 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2
13 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2
14 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2
15 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2
16 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2
17 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2
18 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2
19 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2
20 Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Active, not recruiting NCT01229943 Phase 2
21 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Active, not recruiting NCT01010126 Phase 2
22 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2
23 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2
24 YF476 and Type II Gastric Carcinoids Enrolling by invitation NCT02454075 Phase 2
25 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2
26 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2
27 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2
28 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2
29 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2
30 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2
31 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
32 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1
33 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
34 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1
35 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1
36 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
37 Laser Tissue Welding - Distal Pancreatectomy Sealing Study Recruiting NCT03147768 Phase 1
38 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Active, not recruiting NCT00655655 Phase 1
39 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Not yet recruiting NCT02831179 Phase 1
40 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
41 Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors Unknown status NCT00730483
42 Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome Completed NCT00001254
43 Treatment of Zollinger-Ellison Syndrome Completed NCT00001241
44 Nexium Capsules Clinical Experience Investigation Completed NCT01434485
45 Evaluating Patients With Abnormal Levels of Gastric Acid Completed NCT00001240
46 Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan Enrolling by invitation NCT02102893

Search NIH Clinical Center for Pancreatic Gastrinoma

Genetic Tests for Pancreatic Gastrinoma

Anatomical Context for Pancreatic Gastrinoma

MalaCards organs/tissues related to Pancreatic Gastrinoma:

39
Liver, Lymph Node

Publications for Pancreatic Gastrinoma

Articles related to Pancreatic Gastrinoma:

id Title Authors Year
1
Management of pancreatic gastrinoma associated with Von Hippel-Lindau disease: a case report. ( 27055912 )
2016
2
An esophageal gastrointestinal stromal tumor in a patient with MEN1-related pancreatic gastrinoma: an unusual association and review of the literature. ( 25022420 )
2014
3
Sonic hedgehog and pancreatic-duodenal homeobox 1 expression distinguish between duodenal and pancreatic gastrinomas. ( 19240184 )
2009
4
A rare surgical case of multiple liver resections for recurrent liver metastases from pancreatic gastrinoma: liver and vena cava resection. ( 19267257 )
2009
5
Putative auto-infarct of a pancreatic gastrinoma: a case report. ( 19089667 )
2007
6
Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1. ( 7491542 )
1995
7
Multiple endocrine neoplasia type II with Zollinger-Ellison syndrome caused by a solitary pancreatic gastrinoma. ( 2567786 )
1989
8
Favourable response to conservative surgery for extra-pancreatic gastrinoma with lymph node metastases. ( 3567510 )
1987

Variations for Pancreatic Gastrinoma

Expression for Pancreatic Gastrinoma

Search GEO for disease gene expression data for Pancreatic Gastrinoma.

Pathways for Pancreatic Gastrinoma

GO Terms for Pancreatic Gastrinoma

Cellular components related to Pancreatic Gastrinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 CHGA GAST GCG GRP POMC PPY
2 secretory granule lumen GO:0034774 9.33 GCG GRP POMC
3 extracellular space GO:0005615 9.28 CHGA GAST GCG GRP POMC PPY

Biological processes related to Pancreatic Gastrinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.62 POMC PPY PTHLH SST
2 decidualization GO:0046697 9.43 GHSR MEN1
3 neuropeptide signaling pathway GO:0007218 9.43 GRP POMC PPY
4 response to food GO:0032094 9.4 GAST GHSR
5 osteoblast development GO:0002076 9.37 MEN1 PTHLH
6 regulation of appetite GO:0032098 9.16 POMC PPY
7 positive regulation of cAMP biosynthetic process GO:0030819 9.13 GCG PTHLH SCT
8 positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway GO:1900738 8.62 CHGA GRP

Molecular functions related to Pancreatic Gastrinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.17 GAST GCG POMC PPY PTHLH SCT

Sources for Pancreatic Gastrinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....